Mayo clinic researchers test novel injection of gene therapy vectors into the kidney

New Rochelle, NY, December 31, 2019–Before gene therapy can be used to treat renal diseases, delivery of therapeutic genes to the kidney must become much more efficient. A novel approach in which three different gene delivery vectors were injected intravenously and directly into the kidneys of mice was reported in an article published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Human Gene Therapy website through January 31, 2020.

Jeffrey Rubin, Tien Nguyen, Kari Allen, Katayoun Ayasoufi, and Michael Barry of the Mayo Clinic coauthored the article entitled “Comparison of Gene Delivery to the Kidney by Adenovirus, Adeno-Associated Virus, and Lentiviral Vectors after Intravenous and Direct Kidney Injections.” As the kidney filters out large compounds from the bloodstream, the researchers chose to study the ability to deliver three different sized vectors via an intravenous route: small adeno-associated virus (AAV) vectors (25 nm), larger adenovirus vectors (100 nm) and lentiviral vectors (120 nm). To bypass this filtering mechanism they also tested two different direct injection routes into the kidney and found these to be superior to intravenous injections. However, some of the vectors were able to leak out of the kidney, creating the possibility for off-target tissue effects. The potential for direct injections opens new possibilities for treating kidney diseases with gene therapy, but additional improvements are needed.

“The great burden of kidney diseases in the U.S .and Europe has yet to be impacted by gene therapy,” says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medi-cal Education and Dean, Provost, and Executive Deputy Chancellor, University of Mas-sachusetts Medical School, Worcester, MA. “The Mayo Clinic team has performed an important head-to-head comparison of currently available gene therapy technology, to identify which may best be used to address this im-portant group of diseases.”

###

Research reported in this publication was supported by the National Institutes of Health un-der Award Number 1F31DK123858-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy and eight other international gene therapy societies, was the first peer-reviewed journal in the field and provides all-inclusive access to the critical pillars of human gene therapy: research, meth-ods, and clinical applications. The Journal is led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Ex-ecutive Deputy Chancellor, University of Massachusetts Medical School, and an es-teemed international editorial board. Human Gene Therapy is available in print and online. Complete tables of contents and a sample issue are available on the Human Gene Therapy website.

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, website.